Assessment of the paradoxical effect of caspofungin in therapy of candidiasis - Wikidata - wikimedia - TriplyDB

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

http://www.wikidata.org/entity/Q42090519

about

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin Comparison of echinocandin antifungals Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia Antifungal pharmacokinetics and pharmacodynamics Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species.Developments in the treatment of candidiasis: more choices and new challenges.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The pharmacology and clinical use of caspofungin.Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Micafungin for the prophylaxis and treatment of Candida infections.When primary antifungal therapy fails.Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolate Paradoxical echinocandin activity: a limited in vitro phenomenon?Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility.Echinocandin pharmacodynamics: review and clinical implications.Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.Echinocandins: production and applications.The Eagle-like effect of echinocandins: what's in a name?Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Mechanisms of Antifungal Drug Resistance.Mechanisms of echinocandin antifungal drug resistance.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Drug resistance mechanisms and their regulation in non-albicans Candida species.Potential Microbiological Effects of Higher Dosing of Echinocandins.Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus.The postantifungal and paradoxical effects of echinocandins against Candida spp.Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates.Candidiasis and the impact of flow cytometry on antifungal drug discovery.Caspofungin-Mediated Growth Inhibition and Paradoxical Growth in Aspergillus fumigatus involve Fungicidal Hyphal Tip Lysis Coupled with Regenerative Intrahyphal Growth and Dynamic Changes in β-1,3-Glucan Synthase Localization.[Strategies for antifungal treatment failure in intensive care units].Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.Fungal echinocandin resistance.Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum.

P2860

Q24674839-42ACF75F-AB01-4282-AC85-4EF8199E749A Q28273738-DE625788-47B2-4C96-AE3C-7332CADBC188 Q30570494-475E5CDE-6C9F-4431-B2BF-46F08199579A Q33320193-6D47474C-6E1B-4025-91B1-9A085F9A46D9 Q34006585-8640233D-080A-494F-BBA3-1F57573F9C3C Q34108585-128BE7D9-933A-4B85-9318-788E7D70D6E9 Q35647724-5F1F00C5-0439-482B-B6BD-52D493BEFF7A Q35647785-19F1C758-D31B-42F3-92A6-3B92D6D90DE4 Q35663841-7730378F-F703-4DF8-8A40-EAA112A3CD6A Q35959484-78D000B7-26C9-4657-9945-61F659A9D517 Q36094887-A0839BD1-79FD-4FB0-9673-FC087126D71C Q36623050-C07D857E-C992-4A17-9917-0734ED22EE99 Q36626518-7A4363EB-E1D2-490B-AC69-E1A96D3028E6 Q36788428-4D706100-BFB8-4C13-B270-F62DDBB14A49 Q37048679-329FD412-ACAC-4D67-B7FE-2EE9F87FF036 Q37124868-378F39E6-BB5E-4189-A15F-5A0C2B550B39 Q37141191-BBB6F601-A383-4301-A0B5-4C15CBEF1B31 Q37159301-16B409A7-08DD-4805-82B5-3195609DCB94 Q37405284-EF7B6FDD-A99D-450B-AC5C-AF6627FEFD24 Q37544444-10463508-0787-44FF-90D1-0EFB1446D90F Q37613000-6416A29B-B976-4D23-9747-3C814520B8AB Q37718385-645AF208-92DF-4B2C-9B3C-79310372CD69 Q38027469-A34F0F55-67EC-47F9-B51B-A4067D9D7546 Q38086769-59E65982-79E7-45D0-BCCA-D5E2C871E596 Q38153458-E9FCF512-6F1A-4B3F-967F-ECC4779AB544 Q38254290-44830A30-CE40-4D82-8D3D-918677E0AFFB Q38266675-D2C55CFC-E91D-4F95-80D8-A0A8B984BBEA Q38550402-49B99599-08CB-4A98-9ADB-7A9D8829A86F Q38586680-9BB74533-716B-43B6-A6EF-1A4AEF9F19FB Q38708362-039D3DBE-8F1F-48F8-9A6B-4693E36AF6F1 Q38942828-5CCBEAD3-17FF-4916-BF2E-7A4EB671B82F Q38999537-7C2A3A75-2B21-47E0-8471-D4EDE03E61C3 Q39619972-62EA0708-EED4-4E86-AB7A-88F0AD4B92B2 Q39977764-9A73302D-9EA4-48CE-8712-3E1E6DDED9EA Q40064579-3C728CC3-351F-4AEB-938C-72B3B101E416 Q40112507-7D53674B-9C63-47EC-93F7-7ACA347DB9A0 Q41010354-D8400E5F-0CC7-4EB7-B1D1-140BB8F287B3 Q41194660-AF7F3A1D-4A64-48AB-8810-9A11D1FE2D4E Q41848811-28E57AA8-9F66-4BF8-B7CC-1AA349781771 Q41963359-86649FC8-6ABC-49BD-9A8E-7E3698BCD821

P2860

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

http://www.wikidata.org/entity/Q42090519

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

@en

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

@nl

type

label

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

@en

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

@nl

prefLabel

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

@en

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

@nl

P1433

Q42090519-247B11A0-B315-457C-B9BF-556538CDFA9C

P1476

Q42090519-D235FF39-C649-4538-A1D9-B3EBBE7E26F0

P2093

Q42090519-0BDD65F4-C6C1-4FBE-A122-618B581DE867

Q42090519-995E0358-AF3E-42AF-8D34-3DAF91D73C9E

Q42090519-9F7505A2-357D-4A7F-A0FB-BB219ADF03A8

Q42090519-E67BF0A1-2D55-4104-A320-CB9ECF426174

P2860

Q42090519-104561AA-32A9-4B9E-8216-F210830FEADF

Q42090519-20F1F3BB-BB7D-44E0-B124-F4E799AD1D7C

Q42090519-348C68A9-1F97-4F64-87DB-EDEAFE4592B8

Q42090519-3E8B4741-0D20-44D9-A2FB-ABCD88854FDF

Q42090519-3FEB2E1B-1F3A-4B3B-AE91-4D41171DEEB6

Q42090519-54249562-6882-41B0-991A-9AF995229C14

Q42090519-77B25EA7-1547-4B6D-8F98-5624D3187636

Q42090519-98A2176E-DCC6-4438-9D9B-40CED2D0AED8

Q42090519-AC78EF88-DA9A-42A8-9DAD-619A7A5E4FB9

Q42090519-AEB27B86-36B0-40B5-8E6F-B23B1710ACB5

P304

Q42090519-67FCEFE7-C376-47DD-953C-3FE0ECD6D7AE

P31

Q42090519-925A014D-40D0-47F6-91CE-2A9C5213D6BE

P356

Q42090519-534E82CB-A76D-409D-A2D2-58AB5F191702

P407

Q42090519-FFF8C07E-3609-48B1-84DC-E8EC7AFEA51C

P433

Q42090519-0BEECCC7-3212-45D6-9594-A04C86E2FB21

P478

Q42090519-4F2439BE-86E7-41D9-A993-AD5D59E24878

P577

Q42090519-E3BB612D-A7AD-4B51-81EE-117444C02305

P698

Q42090519-55BADEAE-A41F-4321-B858-C646DCDF6883

P932

Q42090519-BAAB9DA9-BE97-43C2-B8A7-2DDCD67FF624

P356

AAC.50.4.1293-1297.2006

P1433

Antimicrobial Agents and Chemotherapy

P1476

Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

@en

P2093

David A Stevens

http://www.w3.org/2001/XMLSchema#string

Karl V Clemons

http://www.w3.org/2001/XMLSchema#string

Marife Espiritu

http://www.w3.org/2001/XMLSchema#string

Rachana Parmar

http://www.w3.org/2001/XMLSchema#string

P2860

Problems in dealing with missing data and informative censoring in clinical trials.

Synergy between cilofungin and amphotericin B in a murine model of candidiasis

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

Treatment of murine disseminated candidiasis with L-743,872

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control

Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis.

Worst-rank score analysis with informatively missing observations in clinical trials.

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.

P304

1293-1297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.50.4.1293-1297.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16569843

http://www.w3.org/2001/XMLSchema#string

P932

1426960

http://www.w3.org/2001/XMLSchema#string